High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer
Gloria V. Echeverria(Baylor College of Medicine), Helen Piwnica‐Worms(Centre for Cancer Biology), Jeffrey T. Chang(Tufts University), Michael Peoples(The University of Texas MD Anderson Cancer Center), Zhongqi Ge(The University of Texas MD Anderson Cancer Center), Christopher A. Bristow(The University of Texas MD Anderson Cancer Center), Frederick S. Robinson(The University of Texas MD Anderson Cancer Center), Shirong Cai(Sun Yat-sen University), Giulio Draetta(The University of Texas MD Anderson Cancer Center), Sabrina L. Jeter-Jones(The University of Texas MD Anderson Cancer Center), Emily Powell(The University of Texas MD Anderson Cancer Center), Alessandro Carugo(The University of Texas MD Anderson Cancer Center), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), Vandhana Ramamoorthy(The University of Texas MD Anderson Cancer Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Wenhui Wu(The University of Texas MD Anderson Cancer Center), Stacy Moulder(The University of Texas MD Anderson Cancer Center), Jiansu Shao(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Huan Qiu(Anhui Medical University), Sahil Seth(The University of Texas MD Anderson Cancer Center)
Cited by 149
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991